Société Tunisienne des Maladies Respiratoires et d'Allergologie STMRA - Observational study in Qatar: Pfizer–BioNTech Covid vaccine is 89.5% effective against B.1.1.7 variant and 75.0% effective against B.1.351 variant. Vaccine effectiveness against severe, critical, or fatal disease with any SARS-CoV-2 variant was very high,

Sté Tunisienne des Maladies Respiratoires et d'Allergologie

Cercle des Bureaux - Appartement B 5-3 . 1082 Centre urbain Nord Tunis

Observational study in Qatar: Pfizer–BioNTech Covid vaccine is 89.5% effective against B.1.1.7 variant and 75.0% effective against B.1.351 variant. Vaccine effectiveness against severe, critical, or fatal disease with any SARS-CoV-2 variant was very high,

Zouhair Souissi

6 mai 2021

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants – New England Journal of Medicine Commentary: Pfizer-BioNTech vaccine offers strong protection against key variants of concern, real-world data from Qatar shows – The Washington Post Commentary on Twitter ?GET BOTH DOSES! Great variants & #COVID19 vaccine news—Pfizer/BioNTech vaccine had great efficacy […]

The post Observational study in Qatar: Pfizer–BioNTech Covid vaccine is 89.5% effective against B.1.1.7 variant and 75.0% effective against B.1.351 variant. Vaccine effectiveness against severe, critical, or fatal disease with any SARS-CoV-2 variant was very high, at 97.4%. appeared first on Links Medicus.

Lu 671 fois